Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
H.U. Group Research Institute G.K. currently manages 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. This portfolio is distributed across 3 distinct examiners and 3 distinct art units. The distribution suggests that the company is navigating different specialized silos within the patent office rather than concentrating its efforts under a single supervisory authority.
The busiest examiner for this portfolio is SCHLOOP, ALLISON ELIZABETH, who is responsible for 1 of the pending office actions. Because there are 3 distinct examiners in total, the workload is not concentrated under one person. This dispersion can lead to varied prosecution outcomes as each of the 3 distinct art units may apply different internal guidelines or examination standards.
With 1 busiest examiner pending action assigned to SCHLOOP, ALLISON ELIZABETH, the immediate administrative burden per examiner is limited. The presence of the Biotechnology & Pharmaceuticals technology area confirms that the subject matter is being evaluated from different technical perspectives. This variety requires a flexible strategy to address the specific requirements of each examiner involved. Practitioners should monitor these 3 pending office actions for unique examiner behaviors.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SCHLOOP, ALLISON ELIZABETH | 1 | 63.3% | +47.6% |
| GERIDO, DWAN A | 1 | 58.1% | +30.4% |
| CORDAS, EMILY ANN | 1 | 50.9% | +57.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18165574 | METHOD FOR RECOVERING EXTRACELLULAR VESICLES | GERIDO, DWAN A | 8d |
| 18247806 | ONE OR MORE KINDS OF HLA GENE PRIMERS | SCHLOOP, ALLISON ELIZABETH | — |
| 17787720 | METHOD FOR RECOVERING EXTRACELLULAR VESICLE AND BLOOD COLLECTION VESSEL | CORDAS, EMILY ANN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18165574 | METHOD FOR RECOVERING EXTRACELLULAR VESICLES | GERIDO, DWAN A | 8d |
| 18247806 | ONE OR MORE KINDS OF HLA GENE PRIMERS | SCHLOOP, ALLISON ELIZABETH | — |
| 17787720 | METHOD FOR RECOVERING EXTRACELLULAR VESICLE AND BLOOD COLLECTION VESSEL | CORDAS, EMILY ANN | — |
| Art Unit | Apps |
|---|---|
| 1683 | 1 |
| 1797 | 1 |
| 1600 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18247806 | ONE OR MORE KINDS OF HLA GENE PRIMERS | SCHLOOP, ALLISON ELIZABETH | 1683 | §101§103§112 | Non-Final OA | — | Pending | Apr 04, 2023 |
| 18165574 | METHOD FOR RECOVERING EXTRACELLULAR VESICLES | GERIDO, DWAN A | 1797 | §102§103 | Final Rejection | 8d | Pending | Feb 07, 2023 |
| 17787720 | METHOD FOR RECOVERING EXTRACELLULAR VESICLE AND BLOOD COLLECTION VESSEL | CORDAS, EMILY ANN | 1600 | §103§112Other | Non-Final OA | — | Pending | Jun 21, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialH.U. Group Research Institute G.K. has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Allison Elizabeth Schloop has the most, with 1 of H.U. Group Research Institute G.K.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
